Cargando…

Covid‐19 in the absence of eosinophils: The outcome of confirmed SARS‐COV‐2 infection whilst on treatment with benralizumab

Detalles Bibliográficos
Autores principales:	Francis, Charles H. R., Hearn, Andrew P., Ratnakumar, Sharenja, Taylor, Alexander, Duckitt, Jordan, Ahmed, Usmaan, Dhariwal, Jaideep, Nanzer, Alexandra M., Jackson, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347634/ https://www.ncbi.nlm.nih.gov/pubmed/35491441 http://dx.doi.org/10.1111/all.15334

Ejemplares similares

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
por: Nanzer, Alexandra M., et al.
Publicado: (2020)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Prescribing Patterns and Treatment Adherence in Patients with Asthma During the COVID-19 Pandemic
por: Dhruve, Hetal, et al.
Publicado: (2022)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
por: BLOMBERG, Maria, et al.
Publicado: (2020)

Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab
por: Masaki, Katsunori, et al.
Publicado: (2021)

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection
por: Takano, Tomotsugu, et al.
Publicado: (2021)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)

Case Report: Eosinophilic Bronchiolitis With Eosinophil ETosis in Mucus Plugs Successfully Treated With Benralizumab
por: Sasaki, Hisashi, et al.
Publicado: (2022)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

A case of paradoxical eosinophilic fasciitis in a patient on benralizumab
por: Woodbury, Michael J., et al.
Publicado: (2023)

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
por: Sridhar, Sriram, et al.
Publicado: (2019)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment
por: Lim, Andy K H, et al.
Publicado: (2021)

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
por: Dagher, Rania, et al.
Publicado: (2022)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Eosinophilic granulomatosis with polyangiitis: case report and literature review
por: Alam, Vardah, et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE
por: Schleich, Florence, et al.
Publicado: (2023)

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
por: Liu, Wanshu, et al.
Publicado: (2019)

Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia
por: Izumo, Takehiro, et al.
Publicado: (2020)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma
por: Yamada, Hideyasu, et al.
Publicado: (2021)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report
por: Konstantinou, George N., et al.
Publicado: (2023)

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
por: Matsuno, Osamu, et al.
Publicado: (2022)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
por: Jackson, David J., et al.
Publicado: (2019)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
por: Tsurumaki, Hiroaki, et al.
Publicado: (2019)

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab
por: Minami, Daisuke, et al.
Publicado: (2018)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p9obng4qf98mstbstji9fpqkv7